The Promise and Challenges of Cardiac Stem Cell Therapy

Seminars in Thoracic and Cardiovascular Surgery

Volumn 26, Issue 1, 2014, Pages 44-52

  Ni, Nathan C ^a,b   Li, Ren Ke ^a,b   Weisel, Richard D ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aging; Rejuvenation; Stem cell; Stem cell therapy

Indexed keywords

CD133 ANTIGEN; INTERLEUKIN 10;

AGING; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANGIOGENESIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CARDIAC STEM CELL THERAPY; CELL BASED GENE THERAPY; CELL FUNCTION; CELL REGENERATION; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; EMBRYONIC STEM CELL; HEART FUNCTION; HEART INFARCTION; HEART INJURY; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; MYOBLAST; NONHUMAN; PLURIPOTENT STEM CELL; STEM CELL TRANSPLANTATION; ANIMAL; BIOLOGICAL THERAPY; HEART DISEASES; HEART VENTRICLE REMODELING; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; HEART DISEASES; HUMANS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84902489076     PISSN: 10430679     EISSN: 15329488     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2014.03.001     Document Type: Article

References (55)

1. Li R.-K., Jia Z.-Q., Weisel R.D., et al. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg 1996, 62:654-661.
2. Tomita S., Li R.-K., Weisel R.D., et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999, 100(suppl II):247-256.
3. Li R.-K., Weisel R.D., Mickle D.A.G., et al. Autologous porcine heart cell transplantation improved heart function after a myocardial infarction. J Thorac Cardiovasc Surg 2000, 119:62-68.
4. + cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 2006, 116:1865-1877.
5. Menasche P., Alfieri O., Janssens S., et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: First randomized placebo-controlled study of myoblast transplantation. Circulation 2008, 117:1189-1200.
6. Schachinger V., Erbs S., Elsasser A., et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006, 355:1210-1221.
7. Lipinski M.J., Biondi-Zoccai G.G., Abbate A., et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: A collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol 2007, 50:1761-1767.
8. Reffelmann T., Konemann S., Kloner R.A. Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: Putting it in perspectivewith existing therapy. J Am Coll Cardiol 2009, 53:305-308.
9. Perin E.C., Willerson J.T., Pepine C.J., et al. Cardiovascular Cell Therapy Research Network (CCTRN). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The FOCUS-CCTRN trial. J Am Med Assoc 2012, 307:1717-1726.
10. + bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: Safety and efficacy studies. J Thorac Cardiovasc Surg 2007, 133:717-725.
11. Yerebakan C., Kaminski A., Westphal B., et al. Impact of preoperative left ventricular function and time from infarction on the long-term benefits after intramyocardial CD133(+) bone marrow stem cell transplant. J Thorac Cardiovasc Surg 2011, 142:1530-1539. [e3].
12. Donndorf P., Steinhoff G. CD133-positive cells for cardiac stem cell therapy: Current status and outlook. Adv Exp Med Biol 2013, 777:215-227.
13. Donndorf P., Kaminski A., Tiedemann G., et al. Validating intramyocardial bone marrow stem cell therapy in combination with coronary artery bypass grafting, the PERFECT phase III randomized multicenter trial: Study protocol for a randomized controlled trial. Trials 2012, 13:99.
14. Malliaras K., Makkar R.R., Smith R.R., et al. Intracoronary cardiosphere-derived cells after myocardial infarction: Evidence for therapeutic regeneration in the final 1-year results of the CADUCEUS trial. J Am Coll Cardiol 2013.
15. Bolli R., Chugh A.R., D'Amario D., et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial. Lancet 2011, 378:1847-1857.
16. Horvath K.A., Smith W.J., Laurence R.G., et al. Recovery and viability of an acute myocardial infarct after transmyocardial laser revascularization. J Am Coll Cardiol 1995, 25:258-263.
17. Stewart D.J., Kutryk M.J., Fitchett D., et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: Results of the NORTHERN trial. Mol Ther 2009, 17:1109-1115.
18. Yau T.M., Kim C., Li G., et al. Enhanced angiogenesis with multimodal cell-based gene therapy. Ann Thorac Surg 2007, 83:1110-1119.
19. Mathison M.P., Gersch R.P, Nasser A., et al. In vivo cardiac cellular reprogramming efficacy is enhanced by angiogenic preconditioning of the infarcted myocardium with vascular endothelial growth factor. J Am Heart Assoc 2012, 1:e005652.
20. Rosengart T.K., Fallon E., Crystal R.G. Cardiac biointerventions: Whatever happened to stem cell and gene therapy?. Innovations 2012, 7:173-179.
21. Spiegelstein D., Kim C., Zhang Y., et al. Combined transmyocardial revascularization and cell-based angiogenic gene therapy increases transplanted cell survival. Am J Physiol Heart Circ Physiol 2007, 293:H3311-H3316.
22. Ieda M., Fu J.D., Delgado-Olguin P., et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010, 142:375-386.
23. Hatzistergos K.E., Quevedo H., Oskouei B.N., et al. Bone marrow mesenchymal stem cells stimulate cardiac stem cell proliferation and differentiation. Circ Res 2010, 107:913-922.
24. Kan C.D., Li S.-H., Weisel R.D., et al. Recipient age determines the cardiac functional improvement achieved by skeletal myoblast transplantation. J Am Coll Cardiol 2007, 50:1086-1092.
25. Zhuo Y., Li S.-H., Chen M.-S., et al. Aging impairs the angiogenic response to ischemic injury and the activity of implanted cells: Combined consequences for cell therapy in older recipients. J Thorac Cardiovasc Surg 2010, 139:1286-1294.
26. Stolzing A., Jones E., McGonagle D., et al. Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies. Mech Ageing Dev 2008, 129:163-173.
27. Zhang H., Fazel S., Tian H., et al. Increasing donor age adversely impacts beneficial effects of bone marrow, but not smooth muscle myocardial cell therapy. Am J Physiol Heart Circ Physiol 2005, 289:H2089-H2096.
28. Ksiazek K. A comprehensive review on mesenchymal stem cell growth and senescence. Rejuvenation Res 2009, 12:105-116.
29. Liang Y., Van Zant G., Szilvassy S.J. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood 2005, 106:1479-1487.
30. Brunt K.R., Zhang Y., Mihic A., et al. Role of wnt/β-catenin signaling in rejuvenating myogenic differentiation of aged mesenchymal stem cells from cardiac patients. Am J Pathol 2012, 181:2067-2078.
31. Yao J., Jiang S.-L., Liu W., et al. Tissue inhibitor of matrix metalloproteinase-3 or vascular endothelial growth factor transfection of aged human mesenchymal stem cells enhances cell therapy after myocardial infarction. Rejuvenation Res 2012, 15:495-506.
32. Mohsin S., Khan M., Nguyen J., et al. Rejuvenation of human cardiac progenitor cells with Pim-1 kinase. Circ Res 2013, 113:1169-1179.
33. Kang K., Sun L., Xiao Y., et al. Aged human cells rejuvenated by cytokine-enhancement of biomaterials for surgical ventricular restoration. J Am Coll Cardiol 2012, 60:2237-2249.
34. Bartunek J., Behfar A., Dolatabadi D., et al. Cardiopoietic stem cell therapy in heart failure: The C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 2013, 61:2329-2338.
35. Quevedo H.C., Hatzistergos K.E., Oskouei B.N., et al. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A 2009, 106:14022-14027.
36. Hare J.M., Fishman J.E., Gerstenblith G., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial. J Am Med Assoc 2012, 308:2369-2379.
37. Huang X.-P., Sun Z., Miyagi Y., et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 2010, 122:2419-2429.
38. Dhingra S., Li P., Huang X.P., et al. Preserving prostaglandin E2 level prevents rejection of implanted allogeneic mesenchymal stem cells and restores postinfarction ventricular function. Circulation 2013, 128(suppl 1):S69-S78.
39. Spaggiari G.M., Capobianco A., Abdelrazik H., et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008, 111:1327-1333.
40. Németh K., Leelahavanichkul A., Yuen P.S.T., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009, 15:42-49.
41. Tseliou E., Pollan S., Malliaras K., et al. Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched rat strains. J Am Coll Cardiol 2013, 61:1108-1119.
42. Burridge P.W., Keller G., Gold J.D., et al. Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 2012, 10:16-28.
43. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
44. Mauritz C., Martens A., Rojas S.V., et al. Induced pluripotent stem cell (iPSC)-derived Flk-1 progenitor cells engraft, differentiate, and improve heart function in a mouse model of acute myocardial infarction. Eur Heart J 2011, 32:2634-2641.
45. Isobe K., Cheng Z., Ito S., et al. Aging in the mouse and perspectives of rejuvenation through induced pluripotent stem cells (iPSCs). Results Probl Cell Differ 2012, 55:413-427.
46. Zhang Y., Wang D., Chen M., et al. Intramyocardial transplantation of undifferentiated rat induced pluripotent stem cells causes tumorigenesis in the heart. PLoS One 2011, 6:e19012.
47. Zhao T., Zhang Z.-N., Rong Z., et al. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
48. Van Zant G., Liang Y. Concise review: Hematopoietic stem cell aging, life span, and transplantation. Stem Cells Transl Med 2012, 1:651-657.
49. Wu Y., Zhao R.C.H. The role of chemokines in mesenchymal stem cell homing to the myocardium. Stem Cell Rev 2012, 8:243-250.
50. Penn M.S., Pastore J., Miller T., et al. SDF-1 in myocardial repair. Gene Ther 2012, 19:583-587.
51. Dong F., Harvey J., Finan A., et al. Myocardial CXCR4 expression is required for mesenchymal stem cell mediated repair following acute myocardial infarction. Circulation 2012, 126:314-324.
52. Li S.-H., Sun Z., Brunt K.R., et al. Reconstitution of aged bone marrow with young cells repopulates cardiac-resident bone marrow derived progenitor cells and prevents cardiac dysfunction after a myocardial infarction. Eur Heart J 2013, 34:1157-1167.
53. Lehrke S., Mazhari R., Durand D.J., et al. Aging impairs the beneficial effect of granulocyte colony-stimulating factor and stem cell factor on post-myocardial infarction remodeling. Circ Res 2006, 99:553-560.
54. Loffredo F.S., Steinhauser M.L., Jay S.M., et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013, 153:828-839.
55. Conboy M.J., Conboy I.M., Rando T.A. Heterochronic parabiosis: Historical perspective and methodological considerations for studies of aging and longevity. Aging Cell 2013, 12:525-530.